Cas9 Stable Cell Line - SU-DHL-6

The SU-DHL-6-Cas9 stable cell line is the preferred model for B-cell lymphoma research. It is established by integrating the Cas9 nuclease into the human SU-DHL-6 cell line. SU-DHL-6 is a lymphoblast-like suspension cell line isolated from the ascites of a 43-year-old male patient with diffuse large B-cell lymphoma (DLBCL). A hallmark of this cell line is the t(14;18)(q32;q21) translocation, leading to constitutive overexpression of the anti-apoptotic protein Bcl-2. Stable expression of Cas9 in SU-DHL-6 ensures that the gene-editing mechanism is always optimal, providing an efficient and reproducible system for CRISPR-mediated genome editing. This stable cell line eliminates the variability and inefficiency associated with transient transfection, ensuring the gene-editing mechanism is stably available in all cells, which is crucial for conducting reproducible functional genomics studies in the context of well-characterized diffuse large B-cell lymphoma (DLBCL).

The primary applications of the SU-DHL-6-Cas9 stable cell line lie in studying the pathogenesis of DLBCL and screening for novel therapeutic targets that can overcome apoptosis resistance. Researchers utilize this system for large-scale CRISPR screening to identify genes that synergize with Bcl-2 inhibitors or enhance tumor cell sensitivity to chemotherapy. The SU-DHL-6-Cas9 cell line is particularly important for constructing homology models, which can be used to study the role of developmental center B cell (GCB) phenotypes and related signaling pathways in tumor progression. Furthermore, it serves as a reliable platform for evaluating the efficacy of novel immunotherapies and exploring the molecular mechanisms of lymphoma cell survival and proliferation.